Cover Image
Market Research Report

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023

Published by MarketsandMarkets Product code 671105
Published Content info 134 Pages
Delivery time: 1-2 business days
Price
Back to Top
Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023
Published: August 1, 2018 Content info: 134 Pages
Description

"The autoinjectors market is projected to grow at a CAGR of 24.2% during the forecast period."

The global autoinjectors market is expected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period. Growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and technological advancements in autoinjector devices are expected to drive the growth of the autoinjectors market. However, the preference for alternative routes of drug delivery such as oral diabetic agents and epinephrine nasal sprays is expected to restrain the growth of this market to a certain extent.

"By therapy, the rheumatoid arthritis segment is expected to grow at the highest CAGR during the study period."

Based on therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The rheumatoid arthritis segment is expected to grow at the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the high prevalence of rheumatoid arthritis across the globe.

"By type, the disposable autoinjectors segment is expected to grow at the highest rate during the forecast period (2018-2023)."

Based on type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the benefits these autoinjectors offer, such as portability, ease of use, and a lower possibility of infection.

"The North American autoinjectors market is expected to grow at the highest CAGR during the forecast period."

North America is expected to witness the highest growth from 2018 to 2023. This can be attributed to the rising prevalence of anaphylaxis, autoimmune diseases, and chronic diseases in the US and Canada; favorable reimbursement scenario; and increasing number of awareness programs in the region.

Break of primary participants was as mentioned below:

The key players in the global autoinjectors market are: Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US), Merck (US), Ypsomed (Switzerland), AstraZeneca (UK), J&J (US), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), Bayer (Germany), and Haselmeier (Switzerland).

Research Coverage:

The report analyzes the autoinjectors market and aims at estimating the market size and future growth potential of this market based on various segments such as therapy, type, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned five strategies.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the autoinjectors market. The report analyzes the market based on therapy, type, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the autoinjectors market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various autoinjectors across regions
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the autoinjectors market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the market
Table of Contents
Product Code: MD 6494

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. YEARS CONSIDERED FOR THE STUDY
    • 1.3.2. MARKETS COVERED
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. key data from primary sources
      • 2.2.2.2. Key industry insights
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. AUTOINJECTORS MARKET OVERVIEW
  • 4.2. AUTOINJECTORS MARKET, BY TYPE, 2018 VS. 2023
  • 4.3. GEOGRAPHIC ANALYSIS: AUTOINJECTORS MARKET, BY THERAPY
  • 4.4. AUTOINJECTORS MARKET, BY END USER, 2018 VS. 2023
  • 4.5. GEOGRAPHIC SNAPSHOT: AUTOINJECTORS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Growing prevalence of targeted therapies
      • 5.2.1.2. Rising incidence of anaphylaxis
      • 5.2.1.3. Increasing number of regulatory approvals
      • 5.2.1.4. Availability of generic versions of autoinjectors
      • 5.2.1.5. Favorable reimbursements and government support
      • 5.2.1.6. Technological advancements and design development
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Preference for alternative drug delivery modes
        • 5.2.2.1.1. Oral diabetic agents and oral insulin
        • 5.2.2.1.2. Epinephrine nasal sprays
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Patent expiry of biologics to drive the demand for biosimilars
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Development of autoinjectors for multiple drug viscosities
      • 5.2.4.2. Lack of proper training for using autoinjectors

6. AUTOINJECTORS MARKET, BY THERAPY

  • 6.1. INTRODUCTION
  • 6.2. RHEUMATOID ARTHRITIS
  • 6.3. MULTIPLE SCLEROSIS
  • 6.4. DIABETES
  • 6.5. ANAPHYLAXIS
  • 6.6. OTHER THERAPIES

7. AUTOINJECTORS MARKET, BY TYPE

  • 7.1. INTRODUCTION
    • 7.1.1. DISPOSABLE AUTOINJECTORS
    • 7.1.2. REUSABLE AUTOINJECTORS

8. AUTOINJECTORS MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. HOME CARE SETTINGS
  • 8.3. HOSPITALS & CLINICS

9. AUTOINJECTORS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. UK
    • 9.3.3. FRANCE
    • 9.3.4. REST OF EUROPE
  • 9.4. ASIA PACIFIC
    • 9.4.1. JAPAN
    • 9.4.2. CHINA
    • 9.4.3. INDIA
    • 9.4.4. ROAPAC
  • 9.5. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. MARKET RANKING OF OEM COMPANIES
  • 10.4. MARKET SHARE ANALYSIS, BY THERAPEUTIC AREA
    • 10.4.1. RHEUMATOID ARTHRITIS
    • 10.4.2. MULTIPLE SCLEROSIS
    • 10.4.3. DIABETES
    • 10.4.4. ANAPHYLAXIS
  • 10.5. COMPETITIVE SCENARIO
    • 10.5.1. PRODUCT LAUNCHES AND APPROVALS
    • 10.5.2. EXPANSIONS
    • 10.5.3. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

11. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, MnM View)*

  • 11.1. ABBVIE
  • 11.2. MYLAN
  • 11.3. ELI LILLY
  • 11.4. YPSOMED
  • 11.5. AMGEN
  • 11.6. BECTON, DICKINSON AND COMPANY
  • 11.7. OWEN MUMFORD
  • 11.8. CONSORT MEDICAL
  • 11.9. HASELMEIER
  • 11.10. SHL GROUP (SCANDINAVIAN HEALTH LIMITED)
  • 11.11. JOHNSON & JOHNSON (J&J)
  • 11.12. TEVA
  • 11.13. ANTARES PHARMA

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3. AVAILABLE CUSTOMIZATIONS
  • 12.4. RELATED REPORTS
  • 12.5. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: RECENT APPROVALS OF AUTOINJECTOR DEVICES ACROSS THE GLOBE
  • TABLE 2: PATENT EXPIRY OF KEY BIOLOGICS
  • TABLE 3: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 4: AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 5: AUTOINJECTORS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 6: AUTOINJECTORS MARKET FOR DIABETES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 7: AUTOINJECTORS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: AUTOINJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 9: COMPARISON OF DISPOSABLE & REUSABLE AUTOINJECTORS
  • TABLE 10: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 11: DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 12: REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 13: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 14: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 15: AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 16: AUTOINJECTORS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 17: NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 18: NORTH AMERICA: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 19: NORTH AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 20: NORTH AMERICA: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 21: AUTOINJECTORS APPROVED BY THE FDA, 2015-2018
  • TABLE 22: US: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 23: US: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 24: US: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 25: CANADA: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 26: CANADA: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 27: CANADA: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 28: PRODUCT APPROVALS IN EUROPE, 2015-2018
  • TABLE 29: EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 30: EUROPE: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 31: EUROPE: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 32: EUROPE: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 33: GERMANY: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 34: GERMANY: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 35: GERMANY: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 36: UK: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 37: UK: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 38: UK: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 39: FRANCE: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 40: FRANCE: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 41: FRANCE: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 42: ROE: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 43: ROE: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 44: ROE: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 45: ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 46: ASIA PACIFIC: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 47: ASIA PACIFIC: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 48: ASIA PACIFIC: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 49: JAPAN: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 50: JAPAN: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 51: JAPAN: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 52: CHINA: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 53: CHINA: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 54: CHINA: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 55: INDIA: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 56: INDIA: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 57: INDIA: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 58: ROAPAC: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 59: ROAPAC: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 60: ROAPAC: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 61: ROW: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 62: ROW: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 63: ROW: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 64: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 65: EXPANSIONS
  • TABLE 66: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

LIST OF FIGURES

  • FIGURE 1: AUTOINJECTORS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: RESEARCH DESIGN
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: RHEUMATOID ARTHRITIS THERAPY SEGMENT TO DOMINATE THE AUTOINJECTORS MARKET IN 2018
  • FIGURE 8: DISPOSABLE AUTOINJECTORS TO ACCOUNT FOR THE LARGEST SHARE OF THE AUTOINJECTORS MARKET IN 2018
  • FIGURE 9: HOME CARE SETTINGS TO DOMINATE THE AUTOINJECTORS MARKET DURING THE FORECAST PERIOD
  • FIGURE 10: NORTH AMERICA TO WITNESS THE HIGHEST MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 11: GROWING PREVALENCE OF TARGETED THERAPIES AND INCREASING NUMBER OF REGULATORY APPROVALS ARE DRIVING MARKET GROWTH
  • FIGURE 12: DISPOSABLE AUTOINJECTORS TO DOMINATE THE MARKET IN 2018
  • FIGURE 13: RHEUMATOID ARTHRITIS THERAPY SEGMENT TO COMMAND THE LARGEST SHARE OF THE AUTOINJECTORS MARKET IN 2018
  • FIGURE 14: HOME CARE SETTINGS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018
  • FIGURE 15: NORTH AMERICA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 16: AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 17: AUTOINJECTORS MARKET, BY THERAPY, 2018 VS. 2023 (USD BILLION)
  • FIGURE 18: AUTOINJECTORS MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 19: AUTOINJECTORS MARKET, BY END USER, 2018 VS. 2023 (USD BILLION)
  • FIGURE 20: NORTH AMERICA TO COMMAND THE LARGEST MARKET SHARE IN 2018
  • FIGURE 21: NORTH AMERICA: AUTOINJECTORS MARKET SNAPSHOT
  • FIGURE 22: EUROPE: AUTOINJECTORS MARKET SNAPSHOT
  • FIGURE 23: ASIA PACIFIC: AUTOINJECTORS MARKET SNAPSHOT
  • FIGURE 24: ROW: AUTOINJECTORS MARKET SNAPSHOT
  • FIGURE 25: MARKET RANKING OF OEM COMPANIES
  • FIGURE 26: STRATEGIES ADOPTED BY MARKET PLAYERS (2014-2018)
  • FIGURE 27: ABBVIE: COMPANY SNAPSHOT (2017)
  • FIGURE 28: MYLAN: COMPANY SNAPSHOT (2017)
  • FIGURE 29: ELI LILLY: COMPANY SNAPSHOT (2017)
  • FIGURE 30: YPSOMED: COMPANY SNAPSHOT (2017)
  • FIGURE 31: AMGEN: COMPANY SNAPSHOT (2017)
  • FIGURE 32: BD: COMPANY SNAPSHOT (2017) 112  
  • FIGURE 33: CONSORT MEDICAL: COMPANY SNAPSHOT (2017)
  • FIGURE 34: JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017)
  • FIGURE 35: TEVA: COMPANY SNAPSHOT (2017)
  • FIGURE 36: ANTARES PHARMA: COMPANY SNAPSHOT (2017)
Back to Top